NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast …
Tag Archives: Memorial Sloan Kettering Cancer Center
July, 2018
December, 2017
-
13 December
Daiichi Sankyo and Puma Collaborate with Major Cancer Center in HER2-Mutated Cancer
TOKYO, BASKING RIDGE, N.J. & LOS ANGELES–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER …
June, 2017
-
1 June
Philips and MSK Enter Partnership on Genome Analytics for Prostate Cancer Precision Medicine
AMSTERDAM and NEW YORK, June 1, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Memorial Sloan Kettering Cancer Center (MSK), the world’s oldest and largest private cancer center, today announced a research collaboration to help improve the understanding of pancreatic cancer and …
August, 2016
-
5 August
Juno Partners with Memorial Sloan Kettering and Eureka Therapeutics for CAR T Cell Therapy in Multiple Myeloma
SEATTLE & NEW YORK & EMERYVILLE, Calif.–(BUSINESS WIRE)–Aug. 4, 2016– Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced today that it has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center(MSK) and Eureka …
March, 2015
-
2 March
FDA Grants Breakthrough Therapy Status to Atara and MSK’s T Cell Therapy
Atara Biotherapeutics, Inc. and partner Memorial Sloan Kettering Cancer Center (MSK) announced that they have received Breakthrough Therapy designation for its promising T cell therapy. The companies said that the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Atara’s optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus …